Precision Therapeutics has a new name, Helomics Corporation, and new $60 million investment provided by HealthCare Royalty Partners (HC Royalty), a global healthcare investment firm.
The change of name, the press release reads, should reflect the company’s new strategic vision, growth strategy and “in-depth approach to characterizing patients’ live and archived cancer cells.”
Helomics is committed to advancing leading-edge and proprietary technology platforms in cellular analysis, genomics, proteomics and bioinformatics combined with a precise and personalized reporting system for tumor profiling and predictive analytics that help physicians to individualize treatment options for their patients.
Also as part of the deal, Helomics got a new management team. Neil J. Campbell was appointed as President and CEO, Dane R. Saglio – Vice President and CFO, and Ed A. Whigham – Vice President of Sales.
Going forward, Helomics will offer a more comprehensive set of services to help physicians individualize treatment options for their patients.Going forward, the company will offer a more comprehensive set of services to help physicians individualize treatment options for their patients. In addition to its core products — ChemoFx, BioSpeciFx and GeneFx — Helomics will offer an expanded platform of Precision Cellular Analytics, genomics and proteomics as well as bioinformatics & personalized analytics, contract research & development and biorepository & banking.
Finally, Helomics will also be actively looking to acquire new and complementary products to enhance its personalized healthcare platform.